MYC and prostate carcinoma: SH-BC-893 also reduced nuclear YAP levels in MYC-CaP, LNCaP, and 22Rv1 prostate cancer cells (Fig. 3D,E; Appendix Fig. S8A) demonstrating that the effect is not restricted to mPCE cells.